Skip to content

EURANDLAB

Active Private limited companyfounded 2013active for 13 yearsRue Tayant 24, 6043 CharleroiKBO/BCE: BE 0518.905.755

Lifetime

13 annual accounts with figures on one time axis
peak of €65,749 in 2016
€7,398▲ €47,354
lowest -€252,312 in 2017
€33,599▼ 96.0%
peak of €24,436 in 2025
€24,436▲ €33,599
€3,409▼ 97.7%
Documentsfilings and deeds
29-08-202629 days late
2025micro format
Gross margin from -€39,956 to €7,398Result from €829,711 to €33,599Equity from -€9,163 to €24,436Debts from €151,249 to €3,409Cash from €3,630 to €470

Key points

from the 2025 annual accounts

Result

€33,599 ▼ 96.0%
€830,0002024€33,6002025

The result fell in 2025: the 2024 profit included a one-off income of €881,124.

Liquidity

5.75 was 0.85 in 2024

Short-term debts fell from €151,249 to €3,409.

Filings

13 annual accounts since 2013
AprilJune31 JulyOctober201520202025

Two of the last ten came late. The 2025 accounts came in latest, 29 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as EURANDLAB has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for EURANDLAB. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

last known board
Director, until 2024
  • 100 sharesdeed of 11-06-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0518905755
Amendment of the articles · Legal-form change · Resignations & appointments changes role from manager to director · acts as permanent representative · holds 100 shares (100%) · General meeting of 31-05-2024 · Gazette deed
New establishment in Charleroi Chaussée Impériale 91
Incorporation Founding capital of €50,000, 100 shares · Founded by · appointed as manager · published on 28-02-2013 · Gazette deed
All 22 events

Comparable companies

same main activity, the nearest in size
Company
EURANDLAB Charleroi €27,845 €7,398 87.8% -
HUVESEARCH Pelt €95,955 €1,033 59.9% -
RTLC Brussels €107,167 -€66 61.9% -
ORTHOPHAR Kortrijk €258,756 €3,807 99.4% -
FYTOBELL Hasselt €122,152 -€55,562 -322.9% -
Alchemich Farma Houthalen-Helchteren €258,120 €51,607 9.6% -
BIOGEM Vielsalm €183,013 €88,985 20.3% -

These companies have the same main activity as EURANDLAB: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are larger than EURANDLAB: total assets between €96,000 and €259,000, founded between 2006 and 2019.

Official details

Source: KBO
Status
Active since 26-02-2013Normal situation
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
Establishment units
2.218.759.2916043 Charleroi, since 26-02-2013
2.345.725.2646060 Charleroi, since 09-05-2023
Financial year end
31 December
Peppol
Reachable since 28-10-2025
Company details

Annual accounts 2025

≈ €55,000estimated
€27,845▼ 80.4%
Filing
Filed on 29-08-2026
Financials

Insights on EURANDLAB

EURANDLAB files the micro format. That format states no turnover. The gross margin rose from -€3,771 in 2013 to €7,398 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about EURANDLAB

What is the company number of EURANDLAB?
The company number of EURANDLAB is 0518.905.755. The VAT number is the same number with BE in front: BE 0518.905.755.
Where is EURANDLAB based?
The registered office is at Rue Tayant 24, 6043 Charleroi.Company details
What does EURANDLAB do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of EURANDLAB?
EURANDLAB is a private limited company (BV).
When was EURANDLAB founded?
EURANDLAB was founded on 26-02-2013.
Is EURANDLAB still active?
Yes, EURANDLAB is an active enterprise in the KBO register.
What is the turnover of EURANDLAB?
The turnover in financial year 2025 is about €55,000. This figure is estimated from the gross margin of €7,398 and 7,102 comparable companies of the same size. It probably lies between €25,000 and €130,000. It is a rough estimate.Financials
Is EURANDLAB profitable?
In financial year 2025, EURANDLAB made a profit of €33,599.
Where can I find the annual accounts of EURANDLAB?
EURANDLAB filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of EURANDLAB due?
EURANDLAB must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.